-
Product Insights
Net Present Value Model: Cejemly
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Cejemly Drug Details Sugemalimab (Cejemly) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (cycloserine + lurasidone hydrochloride)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (cycloserine + lurasidone hydrochloride) Drug Details D-Cycloserine in a fixed dose combination with lurasidone...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – sugemalimab
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry sugemalimab Drug Details Sugemalimab (Cejemly) is an recombinant human anti-PD-L1 monoclonal antibody. It is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – rilimogene galvacirepvec
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry rilimogene galvacirepvec Drug Details Rilimogene galvacirepvec (Prostvac) is under development for the treatment of...
-
Product Insights
Anesthesia Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2021
Anesthesia Devices are used to administer anesthesia during surgery. Anesthesia Devices includes anesthesia machines, anesthesia circuits, breathing filters, breathing bags, anesthesia masks and regional anesthesia disposables. An anesthesia machine is used for administration of anesthetic gases, vapors and for controlling ventilation throughout the anesthetic procedure. It has evolved from a simple pneumatic device to a complex array of mechanical, electrical and computer-controlled components. An anesthesia machine consists of oxygen (O2) flow meter, ventilator, vaporizer (which produces vapor from a volatile...
-
Sector Analysis
Gastric and Gastroesophageal Junction Adenocarcinoma – Global Drug Forecast and Market Analysis to 2029
Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) is the fifth most common form of cancer and the fourth leading cause of cancer-related death worldwide, yet little is known about its exact etiology despite much ongoing research. Notably, G/GEJAC incidence rates are much higher in East Asia, particularly in Japan, China, and Korea. Approximately 90–95% of G/GEJACs are adenocarcinomas, while the rest represent rarer gastric malignancies, such as gastrointestinal stromal tumors, lymphomas, and neuroendocrine tumors. Historically, treatment of G/GEJAC has been mostly...
-
Sector Analysis
OpportunityAnalyzer: Pulmonary Arterial Hypertension – Opportunity Analysis and Forecasts to 2026
Pulmonary arterial hypertension (PAH) is a rare, fatal cardiopulmonary disease with an annual mortality rate of 15%. The disease is a subset (Group 1) within the World Health Organization’s (WHO’s) classification of the different types of pulmonary hypertension (PH). PAH is characterized by an abnormal rise in the resting mean pulmonary arterial pressure (>25mmHg compared with normal levels of around 14mmHg). This increased pressure is caused by pulmonary arterial obstruction due to endothelial dysfunction and vascular remodeling, and leads to...
-
Sector Analysis
Contract Manufacturing Service Agreements – Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion
This report is a brand new publication covering contract service agreements, across a range of different services and manufacturing scales. The number of contract service agreements secured serves as a primary indicator of a CMO's performance. Contract Manufacturing Service Agreements is critical for establishing an understanding of the overall CMO industry, the range of services provided and the features of some of the largest CMOs participating in the industry.
-
Sector Analysis
United States Peripheral Vascular Devices Market Outlook to 2025 – Aortic Stent Grafts, Arteriotomy Closure, Carotid and Renal Artery Stents, Inferior Vena Cava Filters (IVCF), Peripheral Embolic Protection, Peripheral Guidewires, Peripheral Vascular Stents, PTA Balloons Catheters, PTA Peripheral Drug Eluting Balloons (DEB) Catheters, Renal Denervation Catheters, Tip Location Devices and Vascular Grafts
GlobalData’s “United States Peripheral Vascular Devices Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States Peripheral Vascular Devices market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Arteriotomy Closure Devices, Carotid and Renal Artery Stents, Peripheral Embolic Protection Devices, Peripheral Guidewires, Peripheral Vascular Stents, PTA Balloon Catheters, PV Embolization Plugs & Coils and Renal Denervation Catheters. The United States Peripheral Vascular Devices Market report...
-
Sector Analysis
United States Cardiovascular Devices Market Outlook to 2025 – Aortic and Vascular Graft Devices, Atherectomy Devices, Cardiac Assist Devices and Others
GlobalData’s “United States Cardiovascular Devices Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States Cardiovascular Devices market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Aortic and Vascular Graft Devices, Atherectomy Devices, Cardiac Assist Devices, Cardiac Rhythm Management Devices, Cardiovascular Prosthetic Devices, Cardiovascular Surgery Devices, Clot Management Devices, Electrophysiology Devices, Interventional Cardiology, Peripheral Vascular Devices and Prosthetic Heart Valves. The United States Cardiovascular Devices...